Trevi Therapeutics

118 articles with Trevi Therapeutics

• Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

  3/16/2023

  Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced financial results for the quarter and year ended December 31, 2022, as well as provided business updates.

• Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023

  3/9/2023

  Trevi Therapeutics, Inc. today announced that senior management will host a conference call and live audio webcast on Thursday, March 16, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the fourth quarter and full year ended December 31, 2022.

• Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

  3/8/2023

  Trevi Therapeutics, Inc. today announced that on March 7, 2023, the United States Patent and Trademark Office ("USPTO") issued a notice of allowance for nalbuphine ER's method of treatment of chronic cough in IPF.  

• Trevi Therapeutics to Participate in Upcoming March Conferences

  3/6/2023

  Trevi Therapeutics, Inc. today announced senior management will attend and participate in the following March conferences.

• Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023

  2/16/2023

  Trevi Therapeutics, Inc. announced senior leadership will be presenting at the virtual Emerging Growth Conference on Wednesday, February 22, at 10:50 a.m. ET.

• Trevi Therapeutics to Present and Participate in Upcoming February Conferences

  2/2/2023

  Trevi Therapeutics, Inc. today announced senior leadership will attend and present at the following February investor conferences.

• Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences

  1/5/2023

  Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and other chronic cough indications, and for the treatment of prurigo nodularis, announced business updates.

• Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

  12/19/2022

  Trevi Therapeutics, Inc. announced senior leadership will attend and present at the following investor and partnership conferences in January.

• Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

  11/14/2022

  Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis and other chronic cough indications, and for the treatment of prurigo nodularis, announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer.

• Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

  11/10/2022

  Trevi Therapeutics, Inc. announced financial results for the quarter ended September 30, 2022, as well as provided business updates.

• Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference

  11/8/2022

  Trevi Therapeutics, Inc. today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 3:35 p.m. ET.

• Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022

  11/3/2022

  Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2022.

• Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting

  10/27/2022

  Trevi Therapeutics, Inc. today announced data from the full set of subjects from CANAL, a phase 2 trial in idiopathic pulmonary fibrosis (IPF) chronic cough, will be presented as an oral presentation at the upcoming British Thoracic Society's (BTS) Winter Meeting 2022 taking place in London, United Kingdom.

• /C O R R E C T I O N -- Trevi Therapeutics, Inc./

  9/23/2022

  Trevi Therapeutics, Inc. announced the pricing of its underwritten public offering of 14,252,670 shares of its common stock at a public offering price of $1.93 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 14,247,330 shares of common stock at a price of $1.929 per pre-funded warrant, for total proceeds of approximately $55 million, before deducting underwriting discounts and commissions and expenses payable by Trevi.

• Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

  9/19/2022

  Trevi Therapeutics, Inc. today announced positive results from the full set of subjects in its Phase 2 Cough And NALbuphine (CANAL) trial of Haduvio for the treatment of chronic cough in IPF.

• 

  Clinical Catch-Up: Pfizer's Pneumococcal in, Trevi's Chronic Cough Drug and More

  9/19/2022

  ​​​​​​​The past week saw promising developments in candidate therapies for cancer, congenital hyperinsulinism, chronic cough and COVID-19 vaccines.

• Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Trevi Therapeutics, Inc. announced that Jennifer Good, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:30 a.m. ET.

• Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022

  8/30/2022

  Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis, announced that it will host a virtual R&D Day on Monday, September 19, 2022, from 10:00 AM to 12:30 PM Eastern Time.

• Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release

  8/24/2022

  Trevi Therapeutics, Inc. today announced two late-breaking abstracts were accepted for presentation at upcoming fall medical conferences.

• Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

  8/11/2022

  Trevi Therapeutics, Inc. (Nasdaq: TRVI), today announced financial results for the quarter ended June 30, 2022, as well as provided business updates.